Skyrizi for Psoriatic arthritis
Quick answer: Skyrizi is used for Psoriatic arthritis as part of a il-23 inhibitor (monoclonal antibody) treatment regimen. Risankizumab selectively binds the p19 subunit of interleukin-23, blocking Th17-mediated inflammation The specific dosing for Psoriatic arthritis is determined by your prescriber based on individual factors.
Why is Skyrizi used for Psoriatic arthritis?
Skyrizi belongs to the IL-23 inhibitor (monoclonal antibody) class. Risankizumab selectively binds the p19 subunit of interleukin-23, blocking Th17-mediated inflammation This action makes it useful for treating or managing Psoriatic arthritis in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Skyrizi is the right choice for a specific patient depends on the type and severity of Psoriatic arthritis, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Psoriatic arthritis
Common adult dosing range: 150 mg subcutaneously at weeks 0, 4, then every 12 weeks. The actual dose for Psoriatic arthritis depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Skyrizi medicine page.
What to expect
Skyrizi treatment for Psoriatic arthritis typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Psoriatic arthritis
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Skyrizi is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all IL-23 inhibitor (monoclonal antibody) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Skyrizi
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Skyrizi full prescribing information · All IL-23 inhibitor (monoclonal antibody) alternatives
Frequently asked questions
How effective is Skyrizi for Psoriatic arthritis?
Effectiveness varies by individual response, dose, and severity. Skyrizi is one of several treatment options for Psoriatic arthritis, supported by clinical evidence within the il-23 inhibitor (monoclonal antibody) class. Discuss expected response with your prescriber.
How long do I need to take Skyrizi for Psoriatic arthritis?
Treatment duration depends on the nature of Psoriatic arthritis — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Skyrizi when used for Psoriatic arthritis?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Skyrizi for Psoriatic arthritis?
Yes. Multiple medicines and non-drug options exist for Psoriatic arthritis. Alternatives within the il-23 inhibitor (monoclonal antibody) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.